Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

By Sriparna Roy (Reuters) -Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement to offer Eli ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE ... The higher efficacy of Eli Lilly’s Mounjaro and Zepbound is the reason why NVO has been losing market share. Both companies are ...

Lilly offers weight-loss drugs in vials at a discount to fight competition Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the ...

The move marks another escalation of the battle between Lilly and Novo Nordisk in the fast-growing obesity drugs market, where Zepbound is in a head-to-head contest with the latter's Wegovy ...

It remains to be seen whether the data will help Novo Nordisk in its tussle for market share in the obesity market with Lilly, which reported head-to-head data in December showing that Zepbound ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...